<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066530</url>
  </required_header>
  <id_info>
    <org_study_id>AD-203P3</org_study_id>
    <nct_id>NCT04066530</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of AD-203</brief_title>
  <official_title>A Randomized, Double-blinded, Active Controlled, Non-Inferiority, Multicenter, Phase III Clinical Trial to Evaluate the Efficacy and Safety of AD-203 in Patients With Acute or Chronic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addpharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addpharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, active-controlled , randomized, double-blinded, paralleled group
      clinical study to evaluate the efficacy and safety of AD-203 to demonstrate the
      non-inferiority of AD-203 compared with Mucosta tab. in patients with acute or chronic
      gastritis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 4, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A percentage of subjects showed improvement of stomach erosions by the endoscopy.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluate the improvement rate of &quot;Very much improved' and &quot;Much improved&quot; of subjects with stomach erosions.
The definition of &quot;Very Much Improved&quot; is the subjects showed score changed from 4 to 1 or from 3 to 1. And, &quot;Much improved&quot; means the subject showed score changed from 4 to 2 or from 2 to 1.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">472</enrollment>
  <condition>Acute Gastritis</condition>
  <condition>Chronic Gastritis</condition>
  <arm_group>
    <arm_group_label>AD-203</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucosta tab.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-203</intervention_name>
    <description>AD-203 administered two times daily for two weeks</description>
    <arm_group_label>AD-203</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucosta tab.</intervention_name>
    <description>Mucosta tab. administered three times daily for two weeks</description>
    <arm_group_label>Mucosta tab.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age is over 20 years old, under 75 years old, men or women

          -  Patients diagnosed with acute or chronic gastritis by gastroscopy

        Exclusion Criteria:

          -  Patients who is impossible to receive gastroscopy

          -  Patients taking other investigational drugs or participating in other clinical studies
             in 3 months prior to screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JongJae Park, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KyungTae Kim, D.V.M</last_name>
    <phone>+82-31-891-5661</phone>
    <email>ktkim@addpharma.co.kr</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

